CRITICAL PATH INSTITUTE: Form 990, tax year 2018
View the entire original 990 at ProPublica ↗
- Organization
- CRITICAL PATH INSTITUTE (EIN 20-1991334)
- Tax period
- 2018-07-01 to 2019-06-30
- Filed
- 2020-04-29
- IRS object ID
- 202001209349301820
- Schema version
- 2018v3.1
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule I
- Schedule J
- Schedule L
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2020-04-29T19:09:58-05:00 | ReturnTs |
| Tax Period End | 2019-06-30 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 860683059 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | BEACHFLEISCHMAN PC | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1985 E RIVER ROAD SUITE 201 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 85718 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2018-07-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 201991334 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | CRITICAL PATH INSTITUTE | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | CRIT | BusinessNameControlTxt |
| Phone | 5205473440 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1730 EAST RIVER ROAD NO 200 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 857185898 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | KRISTEN SWINGLE | PersonNm |
| Person Title | COO | PersonTitleTxt |
| Phone | 5205473440 | PhoneNum |
| Signature | 2020-04-27 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Person | KELLY L MELTZER CPA | PreparerPersonNm |
| PTIN | P00633511 | PTIN |
| Phone | 5203214600 | PhoneNum |
| Preparation | 2020-04-27 | PreparationDt |
Filing Security Information FilingSecurityInformation
IP Address IPAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| I Pv4 Address | 64.128.200.66 | IPv4AddressTxt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| IP | 2020-04-27 | IPDt |
| IP Tm | 11:19:01 | IPTm |
| IP Timezone | US | IPTimezoneCd |
| Filing License Type | P | FilingLicenseTypeCd |
| At Submission Creation Device Id | 30E46978D2C59AA32200D71C98AB2CF713052E80 | AtSubmissionCreationDeviceId |
| At Submission Filing Device Id | 30E46978D2C59AA32200D71C98AB2CF713052E80 | AtSubmissionFilingDeviceId |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2018 | TaxYr |
| Build TS | 2020-11-19 02:30:22Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | JOSEPH SCHEEREN | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1730 EAST RIVER ROAD NO 200 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 857185898 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $16,797,670 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.C-PATH.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 2004 | FormationYr |
| Legal Domicile State | AZ | LegalDomicileStateCd |
| Activity Or Mission | CREATE AND MANAGE INTERNATIONAL COLLABORATIONS AND DEVELOP NOVEL TOOLS, ENABLING THE FASTER DEVELOPMENT OF SAFER MEDICAL PRODUCTS. | ActivityOrMissionDesc |
| Voting Members Governing Body | 12 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 11 | VotingMembersIndependentCnt |
| Total Employee | 79 | TotalEmployeeCnt |
| Total Volunteers | 11 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $10,019,550 | PYContributionsGrantsAmt |
| CY Contributions Grants | $10,698,823 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $5,164,609 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $5,883,801 | CYProgramServiceRevenueAmt |
| PY Investment Income | $83,667 | PYInvestmentIncomeAmt |
| CY Investment Income | $215,046 | CYInvestmentIncomeAmt |
| PY Other Revenue | $0 | PYOtherRevenueAmt |
| CY Other Revenue | $0 | CYOtherRevenueAmt |
| PY Total Revenue | $15,267,826 | PYTotalRevenueAmt |
| CY Total Revenue | $16,797,670 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $1,359,100 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $2,107,859 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $8,046,940 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $8,456,998 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $0 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $5,105,672 | PYOtherExpensesAmt |
| CY Other Expenses | $4,808,109 | CYOtherExpensesAmt |
| PY Total Expenses | $14,511,712 | PYTotalExpensesAmt |
| CY Total Expenses | $15,372,966 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | $756,114 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $1,424,704 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $14,421,996 | TotalAssetsBOYAmt |
| Total Assets EOY | $17,507,463 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $7,699,611 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $9,360,374 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $6,722,385 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $8,147,089 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | THE CRITICAL PATH INSTITUTE IS A CATALYST IN THE DEVELOPMENT OF NEW APPROACHES THAT ADVANCE MEDICAL INNOVATION AND REGULATORY SCIENCE. THIS IS ACHIEVED BY LEADING TEAMS THAT SHARE DATA, KNOWLEDGE AND EXPERTISE RESULTING IN SOUND, CONSENSUS BASED SCIENCE. | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $12,586,197 | ExpenseAmt |
| Grant | $2,107,859 | GrantAmt |
| Revenue | $5,883,801 | RevenueAmt |
| Desc | SEE SCHEDULE O | Desc |
| Total Program Service Expenses | $12,586,197 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Temp Or Permanent Endowments | 0 | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | 0 | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | Yes (1) | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (1) | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | 0 | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | 0 | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | 0 | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | Yes (1) | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | 0 | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | 0 | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | Yes (1) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (1) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (1) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| IRP Document | 16 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 79 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (1) | ForeignFinancialAccountInd |
| Foreign Country | EI | ForeignCountryCd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | 0 | QuidProQuoContributionsInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Subj To Tax Rmnrtn Ex Prcht Pymt | 0 | SubjToTaxRmnrtnExPrchtPymtInd |
| Subject To Excs Tax Net Invst Inc | 0 | SubjectToExcsTaxNetInvstIncInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 12 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 11 | IndependentVotingMemberCnt |
| Family Or Business Rln | Yes (1) | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | ANNA M MIDKIFF CPA | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 5206478382 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 1730 EAST RIVER ROAD NO 200 | AddressLine1Txt |
| City | TUCSON | CityNm |
| State Abbreviation | AZ | StateAbbreviationCd |
| ZIP | 857185898 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (29 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | OfficerOfficerInd | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|
| D CRAIG BRATER MD | ||||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| HONORABLE JAMES C GREENWOOD | ||||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| KAY HOLCOMBE MS | ||||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| PETER BARTON HUTT LLB LLM | ||||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| MICHAEL KASSER MBA PHD | ||||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| SHAUN A KIRKPATRICK MA | ||||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| ALAN G LEVIN MS CPA | ||||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| RICHARD T MYERS JR | ||||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| PAULA OLSIEWSKI PHD | ||||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| CINDY PARSEGHIAN MBA | ||||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| ALASTAIR JJ WOOD MB CHB | ||||||||
| BOARD MEMBER | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| TIMOTHY R FRANSON MD | ||||||||
| CHAIRPERSON | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| M WAINWRIGHT FISHBURN JR | ||||||||
| VICE CHAIRPERSON | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| JEFFREY E JACOB SM | ||||||||
| DEPUTY CHAIRPERSON | 1.00 | Yes (X) | $0 | $0 | $0 | |||
| MARTHA BRUMFIELD PHD | ||||||||
| CEO/PRESIDENT THRU 04/14/2019 | 40.00 | Yes (X) | $296,638 | $0 | $29,272 | Yes (X) | ||
| JOSEPH SCHEEREN PHARMD | ||||||||
| CEO/PRESIDENT AS OF 04/15/2019 | 40.00 | Yes (X) | $0 | $0 | $0 | Yes (X) | ||
| LEWIS BARBIERI JD | ||||||||
| SECRETARY | 40.00 | $117,553 | $0 | $19,234 | Yes (X) | |||
| STEVEN T BROADBENT MBA | ||||||||
| COO/TREASURER | 40.00 | $200,243 | $0 | $26,831 | Yes (X) | |||
| LYNN HUDSON PHD | ||||||||
| CHIEF SCIENCE OFFICER | 40.00 | $205,384 | $0 | $17,805 | Yes (X) | |||
| JOHN-MICHAEL SAUER PHD | ||||||||
| PROGRAM OFFICER | 40.00 | $195,763 | $0 | $30,865 | Yes (X) | |||
| KLAUS ROMERO MD | ||||||||
| EXECUTIVE DIRECTOR | 40.00 | $169,174 | $0 | $16,075 | Yes (X) | |||
| STEPHEN J COONS PHD | ||||||||
| PROGRAM OFFICER | 40.00 | $225,685 | $0 | $26,157 | Yes (X) | |||
| STEVE ARNERIC PHD | ||||||||
| EXECUTIVE DIRECTOR | 40.00 | $172,952 | $0 | $25,516 | Yes (X) | |||
| RICHARD LIWSKI | ||||||||
| CHIEF TECHNOLOGY OFFICER | 40.00 | $151,213 | $0 | $25,035 | Yes (X) | |||
| DIANE STEPHENSON | ||||||||
| EXECUTIVE DIRECTOR | 40.00 | $171,020 | $0 | $24,949 | Yes (X) | |||
| INISH O'DOHERTY | ||||||||
| EXECUTIVE DIRECTOR | 40.00 | $169,749 | $0 | $15,190 | Yes (X) | |||
| SONYA EREMENCO | ||||||||
| ASSOCIATE DIRECTOR | 40.00 | $157,741 | $0 | $24,083 | Yes (X) | |||
| DANIELA CONRADO | ||||||||
| ASSOCIATE DIRECTOR | 40.00 | $134,743 | $0 | $12,070 | Yes (X) | |||
| MARCO SCHITO | ||||||||
| SCIENTIFIC DIRECTOR | 40.00 | $133,863 | $0 | $18,839 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $2,501,721 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $311,921 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 24 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| RTI HEALTH SOLUTIONS | |||||
| 200 PARK OFFICERS DRIVE | RESEARCH TRIANGLE PARK | NC | 27709 | RESEARCH | $389,277 |
| LOTOS NILE | |||||
| PO BOX 90245 | NASHVILLE | TN | 37209 | MARKETING | $144,228 |
| AMY C PORTER | |||||
| 4201 N QUAIL CANYON DR | TUCSON | AZ | 85750 | SCIENTIFIC WRITING | $143,950 |
| EPHIBIAN | |||||
| 3180 N SWAN RD | TUCSON | AZ | 85712 | IT SERVICES | $131,445 |
| KORN FERRY | |||||
| NW 5854 PO BOX 1450 | MINNEAPOLIS | MN | 554855854 | RECRUITING | $127,767 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 13 | CntrctRcvdGreaterThan100KCnt |
| Government Grants | $3,770,446 | GovernmentGrantsAmt |
| All Other Contributions | $6,928,377 | AllOtherContributionsAmt |
| Total Contributions | $10,698,823 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp (2 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt |
|---|---|---|---|
| RESEARCH SUPPORT FEES | 541700 | $5,835,771 | $5,835,771 |
| OTHER REVENUE | 900099 | $48,030 | $48,030 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $5,883,801 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $215,046 | TotalRevenueColumnAmt |
| Exclusion | $215,046 | ExclusionAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $16,797,670 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $5,883,801 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $215,046 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Info In Schedule O Part IX | Yes (X) | InfoInScheduleOPartIXInd |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,911,647 | TotalAmt |
| Program Services | $1,911,647 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $196,212 | TotalAmt |
| Program Services | $196,212 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,992,133 | TotalAmt |
| Program Services | $1,224,986 | ProgramServicesAmt |
| Management And General | $767,147 | ManagementAndGeneralAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $5,150,234 | TotalAmt |
| Program Services | $3,942,006 | ProgramServicesAmt |
| Management And General | $1,208,228 | ManagementAndGeneralAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $383,337 | TotalAmt |
| Program Services | $294,649 | ProgramServicesAmt |
| Management And General | $88,688 | ManagementAndGeneralAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $432,513 | TotalAmt |
| Program Services | $322,320 | ProgramServicesAmt |
| Management And General | $110,193 | ManagementAndGeneralAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $498,781 | TotalAmt |
| Program Services | $363,911 | ProgramServicesAmt |
| Management And General | $134,870 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $23,784 | TotalAmt |
| Program Services | $21,462 | ProgramServicesAmt |
| Management And General | $2,322 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $48,892 | TotalAmt |
| Program Services | $36,272 | ProgramServicesAmt |
| Management And General | $12,620 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,032,457 | TotalAmt |
| Program Services | $2,007,948 | ProgramServicesAmt |
| Management And General | $24,509 | ManagementAndGeneralAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $213,210 | TotalAmt |
| Program Services | $155,558 | ProgramServicesAmt |
| Management And General | $57,652 | ManagementAndGeneralAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $385,310 | TotalAmt |
| Program Services | $350,197 | ProgramServicesAmt |
| Management And General | $35,113 | ManagementAndGeneralAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $500,061 | TotalAmt |
| Program Services | $438,017 | ProgramServicesAmt |
| Management And General | $62,044 | ManagementAndGeneralAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $551,859 | TotalAmt |
| Program Services | $333,730 | ProgramServicesAmt |
| Management And General | $218,129 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $493,458 | TotalAmt |
| Program Services | $465,173 | ProgramServicesAmt |
| Management And General | $28,285 | ManagementAndGeneralAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $441,368 | TotalAmt |
| Program Services | $432,059 | ProgramServicesAmt |
| Management And General | $9,309 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $26,250 | TotalAmt |
| Program Services | $19,152 | ProgramServicesAmt |
| Management And General | $7,098 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $45,166 | TotalAmt |
| Program Services | $32,953 | ProgramServicesAmt |
| Management And General | $12,213 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (2 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt |
|---|---|---|---|
| DUES AND SUBSCRIPTIONS | $32,061 | $27,418 | $4,643 |
| MISCELLANEOUS | $14,233 | $10,527 | $3,706 |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $15,372,966 | TotalAmt |
| Program Services | $12,586,197 | ProgramServicesAmt |
| Management And General | $2,786,769 | ManagementAndGeneralAmt |
| Fundraising | $0 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,026,764 | BOYAmt |
| EOY | $4,891,967 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,831,456 | BOYAmt |
| EOY | $5,019,135 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $166,823 | BOYAmt |
| EOY | $385,302 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $596,248 | BOYAmt |
| EOY | $518,992 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $92,347 | BOYAmt |
| EOY | $102,576 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $663,569 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $586,811 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $83,171 | BOYAmt |
| EOY | $76,758 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $5,615,214 | BOYAmt |
| EOY | $6,402,760 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $9,973 | BOYAmt |
| EOY | $109,973 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $14,421,996 | BOYAmt |
| EOY | $17,507,463 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $600,978 | BOYAmt |
| EOY | $955,803 | EOYAmt |
Deferred Revenue DeferredRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,098,633 | BOYAmt |
| EOY | $8,404,571 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,699,611 | BOYAmt |
| EOY | $9,360,374 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,722,385 | BOYAmt |
| EOY | $8,147,089 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $6,722,385 | BOYAmt |
| EOY | $8,147,089 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $14,421,996 | BOYAmt |
| EOY | $17,507,463 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | $1,424,704 | ReconcilationRevenueExpnssAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $10,269,811 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $10,197,464 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $10,085,049 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $10,019,550 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $10,698,823 | CurrentTaxYearAmt |
| Total | $51,270,697 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $10,269,811 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $10,197,464 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $10,085,049 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $10,019,550 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $10,698,823 | CurrentTaxYearAmt |
| Total | $51,270,697 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $24,619,913 | SubstantialContributorsTotAmt |
| Public Support Total170 | $26,650,784 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $82,059 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $80,580 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $48,471 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $83,667 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $215,046 | CurrentTaxYearAmt |
| Total | $509,823 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $51,780,520 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $25,365,071 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.51470 | PublicSupportCY170Pct |
| Public Support PY170 | 0.52990 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
Total Grassroots Lobbying TotalGrassrootsLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $15,372,966 | FilingOrganizationsTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $15,372,966 | FilingOrganizationsTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $918,648 | FilingOrganizationsTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $229,662 | FilingOrganizationsTotalAmt |
Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $883,297 | CurrentYearMinus3Amt |
| Current Year Minus2 | $909,814 | CurrentYearMinus2Amt |
| Current Year Minus1 | $875,586 | CurrentYearMinus1Amt |
| Current Year | $918,648 | CurrentYearAmt |
| Total | $3,587,345 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $5,381,018 | LobbyingCeilingAmt |
Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $11,731 | CurrentYearMinus3Amt |
| Current Year Minus2 | $61,348 | CurrentYearMinus2Amt |
| Current Year Minus1 | $60,816 | CurrentYearMinus1Amt |
| Total | $133,895 | TotalAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $220,824 | CurrentYearMinus3Amt |
| Current Year Minus2 | $227,454 | CurrentYearMinus2Amt |
| Current Year Minus1 | $218,897 | CurrentYearMinus1Amt |
| Current Year | $229,662 | CurrentYearAmt |
| Total | $896,837 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,345,256 | GrassrootsCeilingAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART II-A, LINE 1B | FormAndLineReferenceDesc |
| Explanation | C-PATH DOES NOT LOBBY FOR OR AGAINST ANY SPECIFIC LEGISLATION. C-PATH DOES EXPEND A MINOR AMOUNT OF TIME AND MONEY TO EDUCATE LEGISLATORS AND THEIR STAFF IN THE AREA OF DRUG DEVELOPMENT. | ExplanationTxt |
Schedule D IRS990ScheduleD
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $42,014 | OtherCostOrOtherBasisAmt |
| Depreciation | $42,014 | DepreciationAmt |
| Book Value | $0 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $188,718 | OtherCostOrOtherBasisAmt |
| Depreciation | $169,212 | DepreciationAmt |
| Book Value | $19,506 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $432,837 | OtherCostOrOtherBasisAmt |
| Depreciation | $375,585 | DepreciationAmt |
| Book Value | $57,252 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $76,758 | TotalBookValueLandBuildingsAmt |
| Footnote Text | Yes (X) | FootnoteTextInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART X, LINE 2: | FormAndLineReferenceDesc |
| Explanation | FINANCIAL STATEMENT FIN 48 (ASC 740) FOOTNOTE: C-PATH IS EXEMPT FROM INCOME TAXES UNDER BOTH FEDERAL (INTERNAL REVENUE CODE SECTION 501(C)(3)) AND ARIZONA INCOME TAX LAWS, AND IS CLASSIFIED AS OTHER THAN A PRIVATE FOUNDATION UNDER INTERNAL REVENUE CODE SECTION 509(A)(1). INCOME FROM CERTAIN ACTIVITIES NOT DIRECTLY RELATED TO C-PATH'S TAX-EXEMPT PURPOSE, HOWEVER, MAY BE SUBJECT TO TAXATION AS UNRELATED BUSINESS TAXABLE INCOME (UBTI). SHOULD C-PATH EVER BE SUBJECT TO PENALTIES AND INTEREST ASSESSED BY VARIOUS TAXING AUTHORITIES, THEY WOULD BE CLASSIFIED AS MANAGEMENT AND GENERAL EXPENSES. | ExplanationTxt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (2 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Specific Services ProvidedSpecificServicesProvidedTxt | Region Total ExpendituresRegionTotalExpendituresAmt |
|---|---|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | 0 | 0 | GRANTS TO RECIPIENTS LOCATED IN REGION | CLINICAL RESEARCH | $196,212 |
| EUROPE (INCLUDING ICELAND & GREENLAND) | 0 | 0 | INVESTMENT | $100,000 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 0 | SubtotalOfficesCnt |
| Subtotal Employees | 0 | SubtotalEmployeesCnt |
| Continuation Total Office | 0 | ContinuationTotalOfficeCnt |
| Continuation Total Employee | 0 | ContinuationTotalEmployeeCnt |
| Total Office | 0 | TotalOfficeCnt |
| Total Employee | 0 | TotalEmployeeCnt |
| Subtotal Spent | $296,212 | SubtotalSpentAmt |
| Continuation Spent | $0 | ContinuationSpentAmt |
| Total Spent | $296,212 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (3 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt |
|---|---|---|---|
| EUROPE (INCLUDING ICELAND & GREENLAND) - ALBANIA, ANDORRA, AUSTRIA, BELGIUM | CLINICAL RESEARCH | $89,424 | WIRE TRANSFER |
| EUROPE (INCLUDING ICELAND & GREENLAND) | CLINICIAL RESEARCH | $96,785 | WIRE TRANSFER |
| EUROPE (INCLUDING ICELAND & GREENLAND) | CLINICAL RESEARCH | $10,000 | WIRE TRANSFER |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Org | 3 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | Yes (1) | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | Yes (1) | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. | ExplanationTxt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (9 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt |
|---|---|---|---|---|---|---|---|
| BAYLOR RESEARCH INSTITUTE | |||||||
| 2001 BRYAN ST SUITE 2200 | DALLAS | TX | 75201 | 751921898 | 501(C)(3) | $1,055,538 | DEVELOP A HOLLOW FIBER MODEL FOR TUBERCULOSIS RESEARCH |
| REGENTS OF THE UNIVERSITY OF CALIFORNIA | |||||||
| 1855 FOLSOM STREET BOX 0897 | SAN FRANCISCO | CA | 94143 | 946036493 | STATE OF CALIFORNIA | $170,000 | RESEARCH |
| UNIVERSITY OF FLORIDA | |||||||
| PO BOX 113001 | GAINSVILLE | FL | 32611 | 596002052 | STATE OF FLORIDA | $17,000 | RESEARCH |
| CLINICAL DATA INTERCHANGE STANDARDS CONSORTIUM | |||||||
| PO BOX 2068 | ROUND ROCK | TX | 78680 | 043503931 | 501(C)(3) | $137,750 | DEVELOP CLINICAL DATA STANDARDS |
| THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE | |||||||
| 445 N FIFTH STREET SUITE 600 | PHOENIX | AZ | 85004 | 753065445 | 501(C)(3) | $394,953 | DEVELOP THE RESEQ TB INTEGRATED PIPELINE |
| FOUNDATION FOR THE NATIONAL INSTITUTES OF HEALTH INC | |||||||
| 11400 ROCKVILLE PIKE SUITE 600 | NORTH BETHESDA | MD | 20852 | 521986675 | 501(C)(3) | $11,653 | CLINICAL EVALUATION AND QUALIFICATION OF KIDNEY SAFETY BIOMARKERS STUDY |
| NORTHWESTERN UNIVERSITY | |||||||
| 625 N MICHIGAN AVENUE STE 2700 | CHICAGO | IL | 60611 | 362167817 | 501(C)(3) | $77,216 | RESEARCH |
| UNIVERSITY OF ARIZONA | |||||||
| PO BOX 3520 | TUCSON | AZ | 85722 | 742652689 | STATE OF ARIZONA | $30,616 | RESEARCH |
| UNIVERSITY OF UTAH | |||||||
| 295 CHIPETA WAY 1S133 | SALT LAKE CITY | UT | 84108 | 876000525 | STATE OF UTAH | $16,920 | RESEARCH |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 9 | Total501c3OrgCnt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | CRITICAL PATH INSTITUTE ENTERS INTO SUBAWARD AGREEMENTS WITH SUBRECIPIENTS AND REVIEWS PROGRESS DELIVERABLES AND COSTS. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Idemnification Gross Up Pmts | Yes (X) | IdemnificationGrossUpPmtsInd |
| Housing Allowance Or Residence | Yes (X) | HousingAllowanceOrResidenceInd |
| Written Policy Ref T And E Expnss | Yes (1) | WrittenPolicyRefTAndEExpnssInd |
| Substantiation Required | Yes (1) | SubstantiationRequiredInd |
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Written Employment Contract | Yes (X) | WrittenEmploymentContractInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | Yes (1) | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (1) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (12 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MARTHA BRUMFIELD PHD | ||||||||||||||
| CEO/PRESIDENT THRU 04/14/2019 | $296,638 | $0 | $0 | $0 | $0 | $0 | $22,000 | $0 | $7,272 | $0 | $325,910 | $0 | $0 | $0 |
| STEVEN T BROADBENT MBA | ||||||||||||||
| COO/TREASURER | $200,243 | $0 | $0 | $0 | $0 | $0 | $15,612 | $0 | $11,219 | $0 | $227,074 | $0 | $0 | $0 |
| LYNN HUDSON PHD | ||||||||||||||
| CHIEF SCIENCE OFFICER | $205,384 | $0 | $0 | $0 | $0 | $0 | $15,612 | $0 | $2,193 | $0 | $223,189 | $0 | $0 | $0 |
| JOHN-MICHAEL SAUER PHD | ||||||||||||||
| PROGRAM OFFICER | $195,763 | $0 | $0 | $0 | $0 | $0 | $16,259 | $0 | $14,606 | $0 | $226,628 | $0 | $0 | $0 |
| KLAUS ROMERO MD | ||||||||||||||
| EXECUTIVE DIRECTOR | $169,174 | $0 | $0 | $0 | $0 | $0 | $5,119 | $0 | $10,956 | $0 | $185,249 | $0 | $0 | $0 |
| STEPHEN J COONS PHD | ||||||||||||||
| PROGRAM OFFICER | $225,685 | $0 | $0 | $0 | $0 | $0 | $14,736 | $0 | $11,421 | $0 | $251,842 | $0 | $0 | $0 |
| STEVE ARNERIC PHD | ||||||||||||||
| EXECUTIVE DIRECTOR | $172,952 | $0 | $0 | $0 | $0 | $0 | $14,423 | $0 | $11,093 | $0 | $198,468 | $0 | $0 | $0 |
| RICHARD LIWSKI | ||||||||||||||
| CHIEF TECHNOLOGY OFFICER | $151,213 | $0 | $0 | $0 | $0 | $0 | $10,776 | $0 | $14,259 | $0 | $176,248 | $0 | $0 | $0 |
| DIANE STEPHENSON | ||||||||||||||
| EXECUTIVE DIRECTOR | $171,020 | $0 | $0 | $0 | $0 | $0 | $13,955 | $0 | $10,994 | $0 | $195,969 | $0 | $0 | $0 |
| INISH O'DOHERTY | ||||||||||||||
| EXECUTIVE DIRECTOR | $169,749 | $0 | $0 | $0 | $0 | $0 | $13,540 | $0 | $1,650 | $0 | $184,939 | $0 | $0 | $0 |
| SONYA EREMENCO | ||||||||||||||
| ASSOCIATE DIRECTOR | $157,741 | $0 | $0 | $0 | $0 | $0 | $13,194 | $0 | $10,889 | $0 | $181,824 | $0 | $0 | $0 |
| MARCO SCHITO | ||||||||||||||
| SCIENTIFIC DIRECTOR | $133,863 | $0 | $0 | $0 | $0 | $0 | $8,209 | $0 | $10,630 | $0 | $152,702 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (3 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 1A | JOSEPH SCHEEREN RECEIVED A STIPEND FOR HOUSING WHEN HE RELOCATED. THIS WAS GROSSED UP FOR PAYROLL TAXES AND ADDED TO HIS FORM W-2. |
| PART I, LINE 4A | STEVE ARNERIC RECEIVED A PAYMENT IN THE AMOUNT OF $20,801. |
| PART I, LINE 7 | VARIABLE PAY MAY BE ISSUED BASED UPON PERFORMANCE AT THE DISCRETION OF THE DEPARTMENT HEAD. |
Schedule L IRS990ScheduleL
Bus Tr Involve Interested Prsn BusTrInvolveInterestedPrsnGrp
Name Of Interested NameOfInterested
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | AMY PORTER | PersonNm |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Relationship Description | SPOUSE OF JOHN-MICHAEL SAUER, KEY EMPLOYEE | RelationshipDescriptionTxt |
| Transaction | $143,950 | TransactionAmt |
| Transaction | SCIENTIFIC WRITING | TransactionDesc |
| Sharing Of Revenues | 0 | SharingOfRevenuesInd |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (8 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART III, LINE 4A | THE CRITICAL PATH INSTITUTE (C-PATH) IS AN INDEPENDENT, NON-PROFIT ORGANIZATION UNIQUELY DEDICATED TO ADVANCING MULTIPLE ASPECTS OF THE FDA'S CRITICAL PATH INITIATIVE BY CREATING COLLABORATIONS AMONG REGULATORS (SCIENTISTS FROM THE FDA AND EMA), THE REGULATED MEDICAL PRODUCT INDUSTRY, ACADEMIA, PATIENT GROUPS, AND OTHER ORGANIZATIONS THAT ADVANCE MEDICAL INNOVATION THROUGH THE DEVELOPMENT OF TOOLS AND METHODS BASED UPON SOUND, CONSENSUS-BASED SCIENCE. THE ACCOMPLISHMENTS FOR THIS FISCAL YEAR REPORT INCLUDE: CRITICAL PATH FOR ALZHEIMER'S DISEASE (CPAD) DEVELOPS TOOLS AND NOVEL METHODOLOGIES TO ACCELERATE PROGRESS IN THE DEVELOPMENT OF PREVENTION AND TREATMENT STRATEGIES FOR ALZHEIMER'S DISEASE. THIS YEAR'S ACCOMPLISHMENTS INCLUDE: (1) LAUNCHING THE C-PATH INDUSTRY DATA SHARING INITIATIVE, BASED ON CLOSE COLLABORATION WITH FDA AND INDUSTRY MEMBERSHIP. (2) EXPANSION OF THE CONSORTIUM THROUGH THE EXECUTION OF ADDITIONAL DATA SHARING AGREEMENTS AND ENROLLMENT OF NEW INDUSTRY MEMBERS. THE CRITICAL PATH FOR PARKINSON'S (CPP) CONSORTIUM'S GOALS ARE TO DEVELOP QUANTITATIVE MODEL-BASED TOOLS TO ACCELERATE THE TREATMENT OF PARKINSON'S DISEASE, ESPECIALLY FOR THOSE INDIVIDUALS EXPERIENCING THE FIRST CLINICAL SIGNS OF MOTOR SYMPTOM ONSET. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) RECEIVING FEEDBACK FROM THE FDA ENDORSING THE CPP MODELING ANALYSIS PLAN WITH ADVICE TO ACQUIRE PARKINSON'S DISEASE RANDOMIZED CLINICAL TRIALS. (2) AGGREGATING A TOTAL OF 11 CLINICAL TRIAL DATASETS TO ENRICH THE CPP DATABASE AND FURTHER THE DEVELOPMENT OF A PARKINSON'S DISEASE-DRUG-TRIAL MODEL. (3) LAUNCHING THE DIGITAL DRUG DEVELOPMENT TOOLS (3DT) PROJECT WHICH HAS HELD THREE HIGH-IMPACT REGULATORY MEETINGS IN 2019. (4) LAUNCHING TWO NEW TASK FORCES TO AID IN SUPPORTING FUTURE REGULATORY ENGAGEMENT FOR PD DIGITAL DEVICE MEASURES. THE MISSION OF THE CRITICAL PATH TO TB DRUG REGIMENS (CPTR) INITIATIVE IS TO ACCELERATE THE DEVELOPMENT OF NOVEL TB DRUG REGIMENS THAT ARE SAFER, SHORTER, AND MORE EFFICACIOUS THAN THE CURRENT STANDARD OF CARE. THEIR MISSION EXPANDED TO ACCELERATE THE DEVELOPMENT OF A CLINICALLY USEFUL IN VITRO RAPID DRUG SUSCEPTIBILITY ASSAY TO SUPPORT TB REGIMEN DEVELOPMENT AND DEPLOYMENT. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) COMPLETED THE GRAPHICAL USER INTERFACE (GUI) FOR THE LONGITUDINAL TTP DYNAMICS MODEL LINKING TIME-TO-POSITIVITY TO CLINICAL OUTCOMES. (2) DEPLOYED THE RESEQTB WEBSITE (WWW.RESEQTB.ORG), A "ONE-STOP" SOURCE FOR CURATED, AGGREGATED, AND CLINICALLY RELEVANT GENETIC DRUG RESISTANCE DATA, TO SUPPORT THE TUBERCULOSIS DRUG RESISTANCE SURVEILLANCE PROGRAM AT THE WORLD HEALTH ORGANIZATION, EXPANDING ACCESSIBILITY (BEYOND RESEARCHER-LEVEL USE) TO THE RESEQTB DATA PLATFORM AND AVAILABLE BIOINFORMATICS AND VISUALIZATION TOOLS. (3) REANALYZED DATA IN THE RESEQTB PLATFORM TO GENERATE THE ANNUAL UPDATED DRUG RESISTANCE REPORT AND PERFORMED AN ANALYSIS OF NEW DRUG RESISTANCE MUTATIONS IDENTIFIED IN COMPARISON TO LAST YEAR'S REPORT. (4) COMPLETED SEQUENCING COLLABORATION PROJECT WITH TRANSLATIONAL GENOMICS RESEARCH INSTITUTE (TGEN) TO SEQUENCE OVER 8,800 MTB. ISOLATES. (5) AUTOMATED THE RESEQTB BIOINFORMATICS PIPELINE, REDESIGNED THE RELATIONAL DATABASE INFRASTRUCTURE TO OPTIMIZE DATA ANALYTICS, AND DEPLOYED A SCALABLE INSTANCE OF THIS PLATFORM TO THE WORLD HEALTH ORGANIZATION TO SUPPORT THEIR GLOBAL TB DRUG RESISTANCE SURVEILLANCE EFFORT. (6) COMPLETED THE HOLLOW FIBER SYSTEM STAGE II WORK IN WHICH TB MONOTHERAPY AND COMBINATION DRUG THERAPIES WERE COMPARED HEAD-TO-HEAD TO IDENTIFY THE MOST PROMISING REGIMEN COMBINATIONS AND DOSING SCHEDULES. (7) DEPLOYED TB-PACTS 2.0 ENHANCED SEARCH AND QUERY TOOL FOR INTERNAL TESTING. THE DATA COLLABORATION CENTER (DCC) IS A CENTER WITHIN C-PATH TO ENABLE MULTIPLE ORGANIZATIONS TO WORK TOGETHER IN A NEUTRAL SETTING AND SHARE CLINICAL DATA IN ORDER TO OPTIMIZE ITS VALUE IN CREATING NEW INSIGHTS AND TOOLS THAT ACCELERATE DRUG DEVELOPMENT IN AREAS WITH UNMET MEDICAL NEEDS. THE DCC SUPPORTS DATA SHARING PROJECTS ALIGNED WITH SPECIFIC C-PATH CONSORTIA AS WELL AS DATA SHARING INITIATIVES THAT ARE INDEPENDENT OF C-PATH CONSORTIA. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) PARTNERED WITH THE WORLD HEALTH ORGANIZATION (WHO) AND THE FOUNDATION FOR INNOVATIVE NEW DIAGNOSTICS (FIND) TO DEPLOY THE FIRST-EVER DATA PLATFORM FOR GLOBAL SURVEILLANCE OF TUBERCULOSIS RESISTANCE BASED UPON GENOMIC SEQUENCING DATA. THIS PLATFORM LEVERAGES THE TECHNOLOGY DEVELOPED FOR THE RELATIONAL SEQUENCING TB DATA PLATFORM (RESEQTB) AND WILL EQUIP WHO'S GLOBAL TB SURVEILLANCE GROUP WITH A CONSOLIDATED DATA MANAGEMENT TOOL FOR TRACKING DATA ON DRUG-RESISTANT TB ON A GLOBAL SCALE. (2) PARTNERED WITH THE FLINN FOUNDATION TO DEVELOP AND PILOT "PREVENT-HAARM" (HEALTHCARE-ASSOCIATED ANTIMICROBIAL-RESISTANT MICROBES), A FRAMEWORK TO TRACK AND RESPOND TO ANTIMICROBIAL RESISTANCE IN ARIZONA. C-PATH HAS PARTNERED WITH THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE PATHOGEN AND MICROBIOME DIVISION (TGEN-NORTH) TO DESIGN A FRAMEWORK FOR A STATEWIDE HEALTHCARE ASSOCIATED ANTIMICROBIAL RESISTANT MICROBE SURVEILLANCE SYSTEM. (3) PUBLISHED THERAPEUTIC AREA DATA STANDARDS FOR CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA (CDAD) AND THE TREATMENT OF HIV. (4) DEVELOPED A CDISC STANDARD FOR THE EXCHANGE OF NONCLINICAL DATA (SEND) IMPLEMENTATION GUIDE (IG) FOR ANIMAL RULE STUDIES. THE DUCHENNE REGULATORY SCIENCE CONSORTIUM'S (D-RSC) GOAL IS TO SUPPORT COLLABORATIVE RESEARCH AND REGULATORY QUALIFICATION OF NEW DRUG DEVELOPMENT TOOLS FOR DUCHENNE MUSCULAR DYSTROPHY, TO ENABLE THE EARLIEST POSSIBLE PATIENT ACCESS TO NEW TREATMENTS. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) SELECTION OF THE ANALYSIS DATASET, INITIAL STATISTICAL ANALYSIS PLAN, COMPLETION OF DRAFT MODELING ANALYSIS PLAN AND LETTER OF INTENT FOR FDA FIT-FOR-PURPOSE PATHWAY, EMA LETTER OF SUPPORT FOR GLDH AS A LIVER SAFETY BIOMARKER IN PATIENTS WITH UNDERLYING MUSCLE DAMAGE; (2) ACCEPTANCE OF THE LETTER OF INTENT TO FDA FIT-FOR-PURPOSE PATHWAY AND TO EMA QUALIFICATION OF NOVEL METHODOLOGIES PATHWAY. (3) DEVELOPED BASE AND COVARIATE PROGRESSION MODELS FOR 6 ENDPOINTS. (4) PUBLISHED A PAPER ON THE VALUE OF REGULATORY ACCEPTANCE OF MODELS. THE GOAL OF THE ELECTRONIC PATIENT-REPORTED OUTCOME CONSORTIUM (EPROC) IS TO ADVANCE THE SCIENCE OF CLINICAL TRIAL ENDPOINT ASSESSMENT BY COLLABORATIVELY SUPPORTING AND CONDUCTING RESEARCH, DESIGNING AND DELIVERING EDUCATIONAL OPPORTUNITIES, AND DEVELOPING AND DISSEMINATING BEST PRACTICE RECOMMENDATIONS FOR ELECTRONIC COLLECTION OF CLINICAL OUTCOME DATA. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) PARTICIPATED IN EDUCATIONAL ACTIVITIES AT DIA 2019 GLOBAL ANNUAL MEETING, INCLUDING PRESENTING A SHORT COURSE TITLED "ECOA 101: THE WHAT, WHY, AND HOW OF ECOA TO REDUCE BARRIERS TO ADOPTION IN CLINICAL TRIALS. AND HOSTING A FORUM TITLED "TRAINING FOR THE ELECTRONIC CAPTURE OF PRO DATA IN CLINICAL TRIALS:? VIEWS FROM THE EPRO VENDORS, SPONSORS, SITES, AND PATIENTS." (2) LAUNCHED THE ECOA: GETTING BETTER TOGETHER INITIATIVE, WHICH IS A PRE-COMPETITIVE COLLABORATION AMONG C-PATH, CLINICAL TRIAL SPONSORS FROM THE PRO CONSORTIUM, ECOA PROVIDERS AND CROS FROM THE EPRO CONSORTIUM, AND REGULATORS (FDA), TO ADDRESS CHALLENGES WITH THE IMPLEMENTATION OF ELECTRONIC CLINICAL OUTCOME ASSESSMENTS (ECOAS) IN CLINICAL TRIALS THE HUNTINGTON'S DISEASE REGULATORY SCIENCE CONSORTIUM (HD-RSC), IN PARTNERSHIP WITH CHDI FOUNDATION, IS FOCUSED ON THE DEVELOPMENT OF DRUG DEVELOPMENT TOOLS FOR HUNTINGTON'S DISEASE. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) HOLDING AN INAUGURAL PROGRAM MEETING WITH 80+ STAKEHOLDERS IN ATTENDANCE. (2) SUBMITTING RESPONSE TO EMA REGULATORY SCIENCE TO 2025 STRATEGIC REFLECTION. (3) CONTRIBUTING COMMENTS TO THE FDA DRAFT GUIDANCE ON THE USE OF NATURAL HISTORY STUDIES IN DRUG DEVELOPMENT FOR RARE DISEASES. (4) SIGNING ON 4 NEW INDUSTRY MEMBERS AND 2 NEW NON-PROFIT MEMBERS. (5) EXECUTING 3 DATA COLLABORATION AGREEMENTS FOR THE INCLUSION OF 4 OBSERVATIONAL DATASETS. AT THE REQUEST OF THE FDA, C-PATH FORMED AN INTERNATIONAL NEONATAL CONSORTIUM (INC). THE PURPOSE OF THE CONSORTIUM IS TO ACCELERATE THE DEVELOPMENT OF SAFE AND EFFECTIVE THERAPIES FOR NEONATES. INC ENGAGES THE GLOBAL NEONATAL COMMUNITY - FAMILIES, NEONATAL NURSES, ACADEMIC SCIENTISTS, REGULATORS, PHARMACEUTICAL INVESTIGATORS, ADVOCACY ORGANIZATIONS, AND FUNDERS - TO FOCUS ON THE NEEDS OF THE NEONATE. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) INC'S SEIZURE WORKGROUP DEVELOPED RECOMMENDATIONS FOR USE IN A MASTER PROTOCOL TO EVALUATE MEDICATIONS TO TREAT NEONATAL SEIZURES.?(2) INC'S RETINOPATHY OF PREMATURITY (ROP) WORKGROUP DEVELOPED A SCALE TO DEFINE A COMMON SOURCE OF BLINDNESS IN PRETERM INFANTS.?(3) INC'S NECROTIZING ENTEROCOLITIS (NEC) WORKGROUP DEVELOPED A FRAMEWORK TO IDENTIFY AND TREAT NEONATAL GASTROINTESTINAL INJURY. |
| FORM 990, PART III, LINE 4A | THE MULTIPLE SCLEROSIS OUTCOME ASSESSMENTS CONSORTIUM (MSOAC) HAS A GOAL TO OBTAIN REGULATORY QUALIFICATION OF AN IMPROVED CLINICAL OUTCOME ASSESSMENT INSTRUMENT AS A PRIMARY OR SECONDARY ENDPOINT IN CLINICAL TRIALS OF MULTIPLE SCLEROSIS (MS) THERAPIES. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) COMPLETED ANALYSIS ON THE CURATED, REMAPPED, AND AGGREGATED CONTROL AND TREATMENT ARMS OF 16 CLINICAL TRIAL DATASETS. (2) RECEIVED A DRAFT POSITIVE QUALIFICATION OPINION FROM THE CHMP/EMA. THE POLYCYSTIC KIDNEY DISEASE OUTCOMES CONSORTIUM (PKDOC) HAS DEVELOPED AND OBTAINED REGULATORY QUALIFICATION FROM THE U.S. FOOD AND DRUG ADMINISTRATION (FDA) AND THE EUROPEAN MEDICINES AGENCY (EMA) OF TOTAL KIDNEY VOLUME (TKV) AS A PROGNOSTIC BIOMARKER FOR USE IN CLINICAL TRIALS FOR NEW THERAPIES FOR AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD). THE CONSORTIUM CONTINUES TO EXPLORE ALTERNATE CLINICAL ENDPOINTS, INCLUDING A COMPOSITE ENDPOINT, INNOVATIVE CLINICAL TRIAL DESIGNS, AND REGULATORY PATHWAYS TO HELP EXPEDITE NEW THERAPIES IN PKD. THE FDA HAS COMMUNICATED THAT TKV IS A "REASONABLY LIKELY SURROGATE," WHICH MAKES IT ELIGIBLE FOR AN ACCELERATED APPROVAL PROCESS AT THE FDA. SIX NEW COMPANIES ARE NOW WORKING TO DEVELOP THERAPIES FOR THIS DISEASE. THE FDA APPROVED OTSUKA'S DRUG (JYNARQUETM). THIS IS THE FIRST-EVER FDA-APPROVED TREATMENT FOR PKD. ALTHOUGH IT WAS NOT A DIRECT OUTPUT OF PKDOC, THE CONSORTIUM'S WORK POSITIVELY CONTRIBUTED TO ADVANCES IN THE FIELD CONSISTENT WITH THIS SUCCESS STORY. THERE IS RENEWED INTEREST FROM INDUSTRY MEMBERS TO FURTHER EXPAND THE EFFORTS OF THE PKDOC. THE PATIENT-REPORTED OUTCOME CONSORTIUM (PROC) HAS A GOAL TO ESTABLISH AND MAINTAIN A COLLABORATIVE FRAMEWORK WITH APPROPRIATE STAKEHOLDERS FOR THE QUALIFICATION OF PATIENT-REPORTED OUTCOME (PRO) INSTRUMENTS AND OTHER CLINICAL OUTCOME ASSESSMENT (COA) TOOLS THAT WILL BE MADE AVAILABLE FOR USE IN CLINICAL TRIALS WHERE COA-BASED ENDPOINTS ARE USED TO SUPPORT PRODUCT LABELING CLAIMS. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) TWO PRO MEASURES WERE QUALIFIED BY FDA FOR EXPLORATORY USE, FOR THE ASTHMA DAYTIME SYMPTOM DIARY (ADSD) AND THE ASTHMA NIGHTTIME SYMPTOM DIARY (ANSD). (2) FDA INDICATED THAT THE CONSENSUS-BASED HARMONIZED MYELOFIBROSIS SYMPTOM ASSESSMENT MEASURE, THE MYELOFIBROSIS SYMPTOM ASSESSMENT FORM (MFSAF) V4.0 DIARY, WOULD BE ADDED TO FDA'S COA COMPENDIUM. (3) THE PRO CONSORTIUM HAS ISSUED A TOTAL OF 22 LICENSES FOR USE OF PRO CONSORTIUM MEASURES INCLUDING THE SMDDS, THE NSCLCSAQ, AND THE MYELOFIBROSIS SYMPTOM ASSESSMENT FORM V4.0 (MFSAF V4.0). (4) THE FOLLOWING COAS ARE IN VARIOUS STAGES OF THE DEVELOPMENT AND/OR QUALIFICATION PROCESS: UCSD PERFORMANCE-BASED SKILLS ASSESSMENT FOR MILD COGNITIVE IMPAIRMENT (UPSA-MCI), DIARY FOR IRRITABLE BOWEL SYNDROME SYMPTOMS-C (DIBSS-C) FOR CONSTIPATION PREDOMINANT IBS, DIARY FOR IRRITABLE BOWEL SYNDROME SYMPTOMS-D (DIBSS-D) FOR DIARRHEA PREDOMINANT IBS, DIARY FOR IRRITABLE BOWEL SYNDROME SYMPTOMS-M (DIBSS-M) FOR MIXED IBS, AN OPTIMIZED PROMIS PHYSICAL FUNCTION SHORT FORM FOR MS PATIENTS, PEDIATRIC ASTHMA DIARY - OBSERVER (PAD-O), PEDIATRIC ASTHMA DIARY - CHILD (PAD-C), RHEUMATOID ARTHRITIS WG - PROMIS SHORT FORM V1.0 - FATIGUE 10A. THE PREDICTIVE SAFETY TESTING CONSORTIUM HAS A GOAL TO BRING TOGETHER PHARMACEUTICAL COMPANIES TO SHARE AND VALIDATE INNOVATIVE SAFETY TESTING METHODS UNDER ADVISEMENT OF THE U.S. FOOD AND DRUG ADMINISTRATION (FDA), EUROPEAN MEDICINES AGENCY (EMA), AND JAPAN'S PHARMACEUTICALS AND MEDICAL DEVICES AGENCY (PMDA). CURRENTLY PSTC IS FOCUSED ON DEVELOPING AND OBTAINING REGULATORY QUALIFICATION OF IMPROVED CLINICAL SAFETY BIOMARKERS FOR USE IN DRUG DEVELOPMENT. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) IN COOPERATION WITH MT. SINAI AND FDA, INITIATED THE PREDICTOX PRE-CONSORTIUM FOCUSED ON THE DEVELOPMENT OF QUANTITATIVE TOOLS TO BETTER PREDICT CLINICAL SAFETY FOR PRECLINICAL DATA. (2) MET WITH PMDA TO UPDATE ON STATUS OF KIDNEY CLINICAL QUALIFICATION AND REQUEST INITIATING QUALIFICATION FOR GLUTAMATE DEHYDROGENASE AS A BIOMARKER OF DRUG-INDUCED LIVER INJURY. (3) ORGANIZED AND FACILITATED WEBINAR ON ACETAMINOPHEN-INDUCED LIVER TOXICITY MECHANISMS, DIAGNOSIS AND TREATMENT. (4) PRESENTED AT THE WORLD BIOMARKER CONGRESS. THE VISION OF THE QUANTITATIVE MEDICINE PROGRAM IS TO IMPROVE INDIVIDUAL AND POPULATION HEALTH BY TRANSFORMING DRUG DEVELOPMENT THROUGH METHODOLOGICAL INNOVATION, AND TO BECOME A NATIONALLY AND INTERNATIONALLY RECOGNIZED RESOURCE FOR MODEL-INFORMED DRUG DEVELOPMENT (MIDD). THE MISSION OF C-PATH'S QUANTITATIVE MEDICINE IS TO INTEGRATE NON-CLINICAL AND CLINICAL DATA WITH ANALYTICAL EXPERTISE TO SOLVE BOTTLENECKS IN THE DRUG DEVELOPMENT PROCESS. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) ACHIEVED THE FIRST-EVER LETTER OF SUPPORT FOR A QUANTITATIVE DRUG DEVELOPMENT TOOL FOR THE MODEL-BASED TRIAL ENRICHMENT PLATFORM THAT INCORPORATES HIPPOCAMPAL VOLUME AS A PROGNOSTIC BIOMARKER IN ALZHEIMER'S DISEASE TRIALS. (2) RECEIVED CONFIRMATION FROM FDA ON FUNDING FOR THE TWO MIDD COMPONENTS OF THE CORE GRANT TO A) ESTABLISH A POST-DOCTORAL FELLOWSHIP PROGRAM IN MIDD AT C-PATH AND B) DEVELOP AN ONLINE COURSE IN MIDD FOR FDA SCIENTISTS OF VARYING BACKGROUNDS. THE TYPE I DIABETES CONSORTIUM (T1D) IS FOCUSING ON QUALIFYING ISLET AUTOIMMUNITY ANTIBODIES AS SUSCEPTIBILITY/RISK BIOMARKERS TO BE USED IN THE DEVELOPMENT OF THERAPIES FOR THE TREATMENT, AND ULTIMATELY, THE PREVENTION, OF TYPE 1 DIABETES. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) RECEIVED A POSITIVE FDA RESPONSE TO T1DC'S LETTER OF INTENT AND ENCOURAGED TIDC TO PROCEED TO DEVELOP THE QUALIFICATION PLAN. (2) SUBMITTED A FINAL LETTER OF INTENT AND BRIEFING PACKAGE TO EMA. (3) DRAFTED A PLAN FOR THE GENERATION OF THE T1D DISEASE PROGRESSION MODEL REQUIRED TO SUPPORT THE REGULATORY ENDORSEMENT OF THE ISLET AUTOANTIBODIES. THE TRANSPLANTATION THERAPEUTICS CONSORTIUM IS WORKING TO IDENTIFY MECHANISMS AND DRUG DEVELOPMENT TOOLS TO ACCELERATE DRUG DISCOVERY FOR TRANSPLANT PATIENTS, THROUGH THE COLLABORATIVE INVOLVEMENT OF KEY STAKEHOLDERS IN THE FIELD. THE CONSORTIUM IS INITIALLY FOCUSING ON KIDNEY TRANSPLANT BUT MAY EXPAND TO OTHER SOLID ORGAN TRANSPLANTS IN THE FUTURE. THEIR ACCOMPLISHMENTS THIS YEAR INCLUDE: (1) PRESENTED AT CDER OFFICE OF ANTIMICROBIAL PRODUCTS/DIVISION OF TRANSPLANT AND OPHTHALMOLOGY PRODUCTS GRAND SCIENTIFIC ROUNDS WITH APPROXIMATELY 385 FDA PARTICIPANTS. (2) RECEIVED NOTIFICATION OF AWARD OF TWO FDA BROAD AGENCY ANNOUNCEMENT PROPOSALS. (3) CONDUCTED CRITICAL PATH INNOVATION MEETING WITH FDA TO DISCUSS AND ALIGN TTC EFFORTS WITH AGENCY'S PERSPECTIVE ON UNMET NEEDS AND POTENTIAL REGULATORY SOLUTIONS TO CHALLENGES THAT HAVE LED TO STAGNATION OF DRUG DEVELOPMENT IN SOLID ORGAN TRANSPLANTATION. (4) ACQUIRED DATASETS FROM 4 PARTNERS TO DATE. |
| FORM 990, PART VI, SECTION A, LINE 2 | PETER HUTT AND JEFF JACOB HAVE A BUSINESS RELATIONSHIP. WAIN FISHBURN AND JEFF JACOB HAVE A BUSINESS RELATIONSHIP. JEFF JACOB AND SHAUN KIRKPATRICK HAVE A BUSINESS RELATIONSHIP. |
| FORM 990, PART VI, SECTION B, LINE 11B | FORM 990 IS PREPARED BY AN EXTERNAL CPA FIRM USING INFORMATION PROVIDED BY THE ORGANIZATION. THE FORM IS REVIEWED BY THE ORGANIZATION'S DIRECTOR OF FINANCE, COO, PRESIDENT/CEO, THE BOARD AUDIT, FINANCE, AND RISK COMMITTEE, AND THE BOARD OF DIRECTORS PRIOR TO BEING FINALIZED. |
| FORM 990, PART VI, SECTION B, LINE 12C | ALL MEMBERS OF THE BOARD OF DIRECTORS AND ALL OFFICERS OF THE ORGANIZATION ARE REQUIRED TO FILL OUT A CONFLICT OF INTEREST FORM ANNUALLY. THE RESULTS ARE COMPILED AND REVIEWED BY THE BOARD'S AUDIT, FINANCE, AND RISK COMMITTEE. ANY ACTUAL OR PERCEIVED CONFLICTS THAT HAVE THE POTENTIAL TO BIAS ANY DISCUSSIONS OR DECISIONS BY THE BOARD ARE DISCUSSED BY THE BOARD. ANY DIRECTOR WITH A REAL OR POTENTIAL CONFLICT WILL RECUSE THEMSELVES FROM ANY DISCUSSION OR DECISION WHERE THE CONFLICT HAS A BEARING. |
| FORM 990, PART VI, SECTION B, LINE 15 | A BOARD OF DIRECTORS COMPENSATION COMMITTEE MEETS AND REVIEWS EXECUTIVE COMPENSATION ANNUALLY. EVERY FEW YEARS THE COMMITTEE SEEKS AN INDEPENDENT COMPENSATION CONSULTING ORGANIZATION. AFTER THE CONSULTING ORGANIZATION HAS BEEN RETAINED, THE COMPENSATION COMMITTEE RECEIVES THE CONSULTANT'S EXECUTIVE COMPENSATION REVIEWS AND RECOMMENDATIONS. THIS INFORMATION IS THEN USED AS A BASIS FOR THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF DIRECTORS. IN CONNECTION WITH THE HIRING OF OUR NEW CEO IN APRIL 2019, THE SEARCH FIRM UTILIZED FOR RECRUITMENT CONDUCTED A BENCH-MARKING ANALYSIS TO DETERMINE AN APPROPRIATE SALARY. AN OVERALL SALARY PROGRAM FOR EMPLOYEES MUST BE APPROVED BY THE BOARD OF DIRECTORS COMPENSATION COMMITTEE BEFORE IMPLEMENTATION. ALL EMPLOYEE SALARY INCREASES MUST BE APPROVED BY THE PRESIDENT/CEO. |
| FORM 990, PART VI, SECTION C, LINE 19 | ARTICLES OF INCORPORATION CAN BE FOUND ON THE ARIZONA CORPORATION COMMISSION WEBSITE. THE CONFLICT OF INTEREST POLICY AND THE FINANCIAL STATEMENTS (VIA THE ANNUAL REPORT) ARE POSTED ON THE INSTITUTE'S WEBSITE. |
| FORM 990, PART IX, LINE 11G | RESEARCH SUPPORT SERVICES: PROGRAM SERVICE EXPENSES 1,325,218. MANAGEMENT AND GENERAL EXPENSES 594. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 1,325,812. CONSULTING: PROGRAM SERVICE EXPENSES 651,056. MANAGEMENT AND GENERAL EXPENSES 20,513. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 671,569. OTHER PROFESSIONAL FEES: PROGRAM SERVICE EXPENSES 31,674. MANAGEMENT AND GENERAL EXPENSES 3,402. FUNDRAISING EXPENSES 0. TOTAL EXPENSES 35,076. |
Schedule R IRS990ScheduleR
Id Related Org Txbl Corp Tr IdRelatedOrgTxblCorpTrGrp (2 entries)
| Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Foreign PostalForeignAddress/ForeignPostalCd | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Entity TypeEntityTypeTxt | OwnershipOwnershipPct | Controlled OrganizationControlledOrganizationInd | Share Of EOY AssetsShareOfEOYAssetsAmt |
|---|---|---|---|---|---|---|---|---|---|---|
| CRITICAL PATH GLOBAL LTD | ||||||||||
| 20-22 BEDFORD ROW | LONDON | UK | WC1R 4JS | FACILITATE WORK WITH EUROPEAN MEDICINES AGENCY | UK | CRITICAL PATH INSTITUTE | C | 1.00000 | Yes (1) | |
| CRITICAL PATH INSTITUTE LTD | ||||||||||
| 33 SIR JOHN ROGERSONS QUAY | DUBLIN | EI | 2 | FACILITATE WORK WITH EUROPEAN MEDICINES AGENCY | EI | CRITICAL PATH INSTITUTE | C | 1.00000 | Yes (1) | $73,838 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | 0 | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | 0 | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | 0 | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | Yes (1) | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | 0 | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | 0 | DivRelatedOrganizationInd |
| Asset Sale To Other Org | 0 | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | 0 | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | 0 | AssetExchangeInd |
| Rental Of Facilities To Oth Org | 0 | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | 0 | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | 0 | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | 0 | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | 0 | SharingOfFacilitiesInd |
| Paid Employees Sharing | 0 | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | 0 | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | 0 | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | 0 | TransferToOtherOrgInd |
| Transfer From Other Org | 0 | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp
Other Organization Name OtherOrganizationName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | CRITICAL PATH INSTITUTE LTD | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Transaction Type | D | TransactionTypeTxt |
| Involved | $100,000 | InvolvedAmt |
| Method Of Amount Determination | CASH | MethodOfAmountDeterminationTxt |